Charleston, SC -- (SBWIRE) -- 09/18/2013 -- Today’s Penny Stocks wants you, the investor, to have the ability to be informed in your trading decisions. Our website is designed to take you to the information you need to be at the top of your game in trading penny stocks. Today’s Penny Stocks issues news updates on the following stock:- Opko Health Inc.(NYSE:OPK), Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX), Astex Pharmaceuticals, Inc.(NASDAQ:ASTX), PDL BioPharma Inc.(NASDAQ:PDLI)
Opko Health Inc.(NYSE:OPK) managed to keep its fall at -0.13% on below-normal volume of 1.54 million shares. The stock settled at $8.50 after floating in a range of $8.45 to $8.56. Its latest price was $8.50, reaching market capitalization of $2.86 billion. Its 52-week range has been $4.05 to $10.00. Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics.
Has OPK Found The Bottom and Ready To Move Up? Find Out Here
Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX) traded up on a volume of 1.53 million, lower than its standard daily volume. Shares have gained +1.22% to $2.48. Over the last twelve months, the stock has added 125.45% and faced a best price of $2.75. Catalyst Pharmaceutical Partners, Inc. operates as development-stage specialty pharmaceutical company. It focuses on the development and commercialization of novel prescription drugs targeting rare (orphan) neuromuscular and neurological diseases and disorders.
For How Long CPRX will Fight for Profitability? Read This Trend Analysis report
Astex Pharmaceuticals, Inc.(NASDAQ:ASTX) settled -0.12% lower at $8.54 on below-normal volume of 1.50 million shares during the last trading day. The stock has its 12-month high at $9.39 and 52-week low price was $2.14. It traded in a range of $8.52 to $8.65 during the last trading day. Astex Pharmaceuticals, Inc. engages in the discovery and development of small molecule therapeutics with a focus on oncology and hematology using its fragment-based drug discovery platform, Pyramid.
Why Should Investors Buy ASTX After the Recent Fall ? Just Go Here and Find Out
PDL BioPharma Inc.(NASDAQ:PDLI) saw its price gain on below-normal volume, as 1.48 million shares changed hands when compared with its average daily volume of 1.55 million shares. The stock was up +2.03% to $8.04. It has gained over the last 12 months, increasing 6.63% . PDL BioPharma, Inc. engages in intellectual property asset management and patent portfolio and related assets investment activities.
Why Should Investors Buy PDLI After The Recent Gain? Just Go Here and Find Out
About Today’s Penny Stocks:
Today’s Penny Stocks wants you, the investor, to have the ability to be informed in your trading decisions. Our website is designed to take you to the information you need to be at the top of your game in trading penny stocks. Today’s wants you to do your own due diligence on your investments please use our site to find the information you need on whichever investment you choose.
The disclaimer is to be read and fully understood before using our site, or joining our newsletter email list. Never invest into a stock discussed on this web site or the TodaysPennyStocks.com newsletter unless you can afford to lose your entire investment.
Please consult with a certified financial advisor before making any investment decisions.
TodaysPennyStocks.com is owned and operated by FlipVentures LLC. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.
Read Full Disclaimer at: http://todayspennystocks.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)